INCYTE CORPORATION (NASDAQ:INCY) Files An 8-K Results of Operations and Financial Condition

INCYTE CORPORATION (NASDAQ:INCY) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

Story continues below

On February14, 2019,Incyte Corporation issued a press release announcing financial results for its fourth fiscal quarter and year ended December31, 2018. The full text of the press release is furnished as Exhibit99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1

Press release issued by Incyte Corporation dated February14, 2019.

INCYTE CORP Exhibit
EX-99.1 2 a19-4674_1ex99d1.htm EX-99.1 Exhibit 99.1     Incyte Reports 2018 Fourth Quarter and Year-End Financial Results,…
To view the full exhibit click here

About INCYTE CORPORATION (NASDAQ:INCY)

Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The Company’s pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company has discovered multiple potent, selective and orally bioavailable JAK inhibitors that are selective for JAK1 or JAK1 and JAK2. JAKAFI is the compound in its JAK program, which is an oral JAK1 and JAK2 inhibitor. JAKAFI orphan drug is indicated for Myelofibrosis (MF), Polycythemia Vera (PV) and essential thrombocythemia. The Company’s second oral JAK1 and JAK2 inhibitor is baricitinib.

An ad to help with our costs